Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy.


Journal

Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127

Informations de publication

Date de publication:
2022
Historique:
received: 09 10 2021
accepted: 22 12 2021
entrez: 21 1 2022
pubmed: 22 1 2022
medline: 8 4 2022
Statut: epublish

Résumé

This study was conducted to investigate the effect of alpha-fetoprotein (AFP) ratio on the prognosis of AFP-positive hepatocellular carcinoma (HCC) patients after hepatectomy. We retrospectively included 879 HCC patients with AFP-positive who underwent hepatectomy from February 2012 to October 2017 and randomly divided into training cohort and validation cohort. AFP ratio was equal to the AFP level within one week before hepatectomy to AFP level within 20-40 days after surgery. The end point of follow-up was disease-free survival (DFS) and overall survival (OS). AFP ratio was not associated with clinical characteristics in training cohort and validation cohort. According to the X-tile software, the optimum cut-off point was 17.8 for AFP ratio. Significant differences between AFP ratio high and AFP ratio low were observed in DFS and OS in both cohort ( AFP ratio might be a prognosis predictor for HCC patients with AFP-positive after hepatectomy.

Sections du résumé

BACKGROUND BACKGROUND
This study was conducted to investigate the effect of alpha-fetoprotein (AFP) ratio on the prognosis of AFP-positive hepatocellular carcinoma (HCC) patients after hepatectomy.
METHODS METHODS
We retrospectively included 879 HCC patients with AFP-positive who underwent hepatectomy from February 2012 to October 2017 and randomly divided into training cohort and validation cohort. AFP ratio was equal to the AFP level within one week before hepatectomy to AFP level within 20-40 days after surgery. The end point of follow-up was disease-free survival (DFS) and overall survival (OS).
RESULTS RESULTS
AFP ratio was not associated with clinical characteristics in training cohort and validation cohort. According to the X-tile software, the optimum cut-off point was 17.8 for AFP ratio. Significant differences between AFP ratio high and AFP ratio low were observed in DFS and OS in both cohort (
CONCLUSIONS CONCLUSIONS
AFP ratio might be a prognosis predictor for HCC patients with AFP-positive after hepatectomy.

Identifiants

pubmed: 35059044
doi: 10.1155/2022/7640560
pmc: PMC8766187
doi:

Substances chimiques

alpha-Fetoproteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7640560

Informations de copyright

Copyright © 2022 Li-Yue Sun et al.

Déclaration de conflit d'intérêts

The authors declare that there is no conflict of interest regarding the publication of this paper.

Références

PeerJ. 2020 Sep 16;8:e9949
pubmed: 32995093
Int J Cancer. 2004 Oct 20;112(1):44-50
pubmed: 15305374
Front Oncol. 2019 Oct 15;9:1069
pubmed: 31681602
Liver Cancer. 2019 Oct;8(5):403-411
pubmed: 31768348
Cancer Manag Res. 2018 Sep 20;10:3707-3715
pubmed: 30288102
Cancers (Basel). 2021 Apr 02;13(7):
pubmed: 33918270
BMC Surg. 2014 Jul 04;14:40
pubmed: 24993566
Cancer Sci. 2019 Jun;110(6):2033-2043
pubmed: 30919528
Oncol Rep. 2010 Aug;24(2):521-8
pubmed: 20596642
Oncologist. 2017 May;22(5):561-569
pubmed: 28438885
Sci Rep. 2020 Aug 11;10(1):13519
pubmed: 32782270
Cell Death Dis. 2020 Oct 2;11(10):822
pubmed: 33009373
Lancet. 2019 Sep 28;394(10204):1145-1158
pubmed: 31248666
World J Clin Cases. 2018 Jun 16;6(6):110-120
pubmed: 29988930
Cell Death Dis. 2020 Oct 22;11(10):901
pubmed: 33093455
PLoS One. 2020 Jul 2;15(7):e0235576
pubmed: 32614912
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Intervirology. 2008;51 Suppl 1:86-94
pubmed: 18544953
Transl Gastroenterol Hepatol. 2019 Jul 11;4:52
pubmed: 31463411
J Surg Oncol. 1992 Mar;49(3):151-5
pubmed: 1372375
Hepatology. 1998 Sep;28(3):751-5
pubmed: 9731568
Front Oncol. 2020 Apr 21;10:496
pubmed: 32426269

Auteurs

Li-Yue Sun (LY)

Second Department of Oncology, Guangdong Second Provincial General Hospital, 466 Xingang-Zhong Road, Guangzhou, China.

Wen-Jian Cen (WJ)

State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China.

Wen-Ting Tang (WT)

State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China.

Ling Deng (L)

State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China.

Fang Wang (F)

State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China.

Xiao-Meng Ji (XM)

State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China.

Jiao-Jiao Yang (JJ)

State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China.

Ren-Jing Zhang (RJ)

State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China.

Xu-Hui Zhang (XH)

Second Department of Oncology, Guangdong Second Provincial General Hospital, 466 Xingang-Zhong Road, Guangzhou, China.

Zi-Ming Du (ZM)

State Key Laboratory of Oncology in South China, Guangzhou, China.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Molecular Diagnostics, Sun Yat-sen University Cancer Center, Guangzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH